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Available online 13 January 2016Background: Following activation by vitamin K (VK), matrix Gla protein (MGP) inhibits arterial calciﬁcation, but
its role in preserving renal function remains unknown.
Methods: In 1166white Flemish (mean age, 38.2 years) and 714 South Africans (49.2% black; 40.6 years), we cor-
related estimated glomerular ﬁltration (eGFR [CKD-EPI formula]) and stage of chronic kidney disease (CKD
[KDOQI stages 2–3]) with inactive desphospho-uncarboxylated MGP (dp-ucMGP), using multivariable linear
and logistic regression.
Results: Among Flemish and white and black Africans, between-group differences in eGFR (90, 100 and
122 mL/min/1.73 m2), dp-ucMGP (3.7, 6.5 and 3.2 μg/L), and CKD prevalence (53.5, 28.7 and 10.5%)
were signiﬁcant, but associations of eGFR with dp-ucMGP did not differ among ethnicities (P ≥ 0.075).
For a doubling of dp-ucMGP, eGFR decreased by 1.5 (P = 0.023), 1.0 (P = 0.56), 2.8 (P = 0.0012)
and 2.1 (P b 0.0001) mL/min/1.73 m2 in Flemish, white Africans, black Africans and all participants combined;
the odds ratios for moving up one CKD stage were 1.17 (P= 0.033), 1.03 (P= 0.87), 1.29 (P= 0.12) and 1.17
(P= 0.011), respectively.
Interpretation: In the general population, eGFR decreases and CKD risk increaseswith higher dp-ucMGP, amarker
of VK deﬁciency. These ﬁndings highlight the possibility that VK supplementation might promote renal health.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Vitamin K1. Introduction
Vascular smooth muscle cells synthesize matrix Gla protein
(MGP), a small secretory protein (11 kD), which contains ﬁve
γ-carboxyglutamate (Gla) amino-acid residues (Hackeng et al.,
2001). Activation of MGP requires two posttranslational modiﬁca-
tions: the vitamin-K dependent γ-glutamate carboxylation and
serine phosphorylation (Schurgers et al., 2008). Carboxylated MGPre, Research Unit Hypertension
nt of Cardiovascular Diseases,
voer 35, Box 7001, BE-3000
aessen@maastrichtuniversity.nl
. This is an open access article underis a potent inhibitor of arterial calciﬁcation (Schurgers et al., 2008). In
patients with diabetes (Dalmeijer et al., 2013), renal dysfunction,
(Schurgers et al., 2010) or macrovascular disease (Mayer et al., 2014),
inactive desphospho-uncarboxylated MGP (dp-ucMGP) behaves as a
circulating biomarker associated with cardiovascular risk (Dalmeijer
et al., 2013), more severe vascular illness (Schurgers et al., 2010), and
higher mortality (Mayer et al., 2014). In the Flemish Study on Environ-
ment, Genes and Health Outcomes (FLEMENGHO), circulating dp-
ucMGP predicted total and cardiovascular mortality (Liu et al., 2015).
Total uncarboxylated MGP (t-ucMGP), in contrast to dp-ucMGP, is not
a marker of vitamin K status, but reﬂects arterial calciﬁcation, lower
values being associated with more widespread calcium deposits
(Cranenburg et al., 2009; Schurgers et al., 2005).
Previous research on MGP focused on macrovascular complications
in patients (Dalmeijer et al., 2013; Schurgers et al., 2010; Mayer et al.,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the kidney with MGP immunoreactivity being associated with the epi-
thelium of Bowman's capsule and the proximal tubules (Fraser and
Price, 1988). Mineral nanoparticles containing calcium phosphate and
calciﬁcation inhibitors are present in kidneys of patients with end-
stage renal disease, but not healthy controls, and probably precede ec-
topic renal calciﬁcation (Wong et al., 2015). Moreover, calciﬁcation of
the arterial wall is the hallmark of renal impairment (Lanzer et al.,
2014; Moe and Chen, 2004) and may involve arterioles with a diam-
eter as small as 10 to 500 μm (Lanzer et al., 2014). Based on these
recent insights (Wong et al., 2015; Lanzer et al., 2014), we hypoth-
esized that renal microvascular traits, such as glomerular ﬁltration
or microalbuminuria (Chade, 2013; Navar et al., 2008), might be ad-
versely affected by deﬁcient vitamin-K dependent activation of MGP,
as exempliﬁed by circulating dp-ucMGP.We investigated our hypothe-
sis in white people enrolled in the FLEMENGHO study (Liu et al., 2015)
and sought replication in the white and black participants enrolled in
the South African Study Regarding the Inﬂuence of Sex, Age and Ethnic-
ity on Insulin Sensitivity and Cardiovascular Function (SAfrEIC) (Kruger
et al., 2012).2. Methods
2.1. Recruitment of Participants
The two population studies complied with the Helsinki declara-
tion for research in human subjects (World Medical Association,
2013), which were approved by the competent local ethics commit-
tees. Participants gave informed written consent. FLEMENGHO is a
large-scale family-based population study, for which recruitment
started in 1985 (participation rate, 78.0%) (Liu et al., 2015). The
3343 participants remained in follow-up, of whom 1179 had plasma
dp-ucMGP and total uncarboxylated MGP (t-ucMGP) and serum
and urinary creatinine and 24-h microalbuminuria measured at
the same follow-up visit (Fig. S1). Black and white SAfrEIC residents
of the Potchefstroom district in the North West Province of South
Africa were recruited in 2007 (Kruger et al., 2012). Via advertise-
ments or solicitation by community workers, apparently healthy
people from 20 to 70 years old were invited (Kruger et al., 2012).
Of 754 applicants complying with the entry criteria, 735 had both
plasma dp-ucMGP and serum creatinine available for analysis. We
excluded participants from analysis (Fig. S1), if they were taking
warfarin (2 Flemish and 4 Africans), if MGP levels were more than
3 SDs away from the population mean (3 Flemish and 8 Africans),
or if required covariables were unavailable (8 Flemish and 9
Africans). Thus, the number of participants statistically analyzed
amounted to 1166 white Flemish and 714 South Africans, whose
self-declared ethnicity was white in 362 and black in 352.2.2. Clinical Measurements
In both the Flemish and African cohorts blood pressure was mea-
sured after participants had rested for at least 5 min in the seated posi-
tion. In FLEMENGHO(Liu et al., 2015), blood pressurewas the average of
ﬁve consecutive auscultatory readings obtainedwith a standardmercu-
ry sphygmomanometer. In SAfrEIC (Schutte et al., 2010), blood pressure
was the average of two oscillometric readings acquired by the OMRON
HEM-757 device (El Assaad et al., 2003) (Omron Healthcare, Kyoto,
Japan). Hypertensionwas a blood pressure of at least 140mmHg systol-
ic or 90 mmHg diastolic, or use of antihypertensive drugs. Trained
nurses administered questionnaires inquiring into each participant's
medical history, smoking and drinking habits, and intake of medica-
tions. Body mass index was weight in kilograms divided by height in
meters squared.2.3. Biochemical Measurements
Blood samples collected from an antecubital vein after the partic-
ipants had been fasting for 6 to 8 h were analyzed for glucose and
the serum levels of total and high-density lipoprotein (HDL) choles-
terol, creatinine and γ-glutamyltransferase (biomarker of alcohol
intake), using automated methods in certiﬁed laboratories. Diabetes
mellitus was a fasting glucose exceeding 7.0 mmol/L (126 mg/dL) or
use of antidiabetic agents (Expert Committee on the Diagnosis and
Classiﬁcation of Diabetes Mellitus, 2003). Estimated glomerular ﬁl-
tration rate (eGFR) was derived from serum creatinine, according
to the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation (Levey et al., 2009). We staged chronic kidney disease
(CKD) according to the National Kidney Foundation (KDOQI) guide-
line (Levey et al., 2005) as eGFR ≥90, 89–60, 59–30 mL/min/1.73 m2.
Flemish participants collected a timed 24-h urine sample for the
measurement of microalbumin and creatinine. Microalbuminuria was
an albumin-to-creatinine ratio of at least 3.5 mg/mmol in women or
2.5 mg/mmol in men (Mancia et al., 2013). Human immunodeﬁciency
virus (HIV) status was determined in South Africanswith rapid tests ac-
cording to the protocol of the National Department of Health (Pretoria)
and conﬁrmed with the Pareeshak test (BHAT Bio-tech, Bangalore,
India) (Kruger et al., 2012).
For measurement of MGP, plasma was immediately separated from
whole blood by 10 min of centrifugation at 1500 g-force. Plasma ali-
quots of 2 mL were deep frozen at −20 °C or −80 °C within 30 min
of blood sampling. For long-term storage exceeding 2 months, all sam-
ples were kept at−80 °C until assayed. dp-ucMGP (both cohorts) and
t-ucMGP (Flemish only) were measured by pre-commercial ELISA kits
at VitaK (Maastricht University, The Netherlands) (Cranenburg et al.,
2010). The concentration of dp-ucMGP was assessed using the inaKtif
MGP iSYS kit (Immunodiagnostic Systems Ltd., Boldon, UK), which is a
dual-antibody test based on the sandwich ELISA developed by VitaK.
Circulating t-ucMGP levels were measured by a competitive mono-
antibody ELISA of the same origin.2.4. Statistical Analyses
For database management and statistical analysis, we used the SAS
system, version 9.4 (SAS Institute Inc., Cary, NC). Signiﬁcance was a
two-tailed α-level of 0.05 or less. Means and proportions were com-
pared using the large-sample z-test or ANOVA and Fisher's exact test,
respectively. We normalized the distributions of dp-ucMGP, t-ucMGP
and γ-glutamyltransferase by a logarithmic transformation.
We determined differences in renal function across thirds of the
MGP distributions from generalized linear models. In multivariable-
adjusted linear and logistic regression with eGFR (continuous) or
stage of chronic kidney disease (categorical) as outcome, we entered
as covariables mean arterial pressure, heart rate, fasting glucose, the
HDL-to-total cholesterol ratio, γ-glutamyltransferase, smoking, and
treatment with antihypertensive drugs. Additional covariables in
South Africans included HIV carrier state and in Flemish antihyperten-
sive drug treatment, broken down into diuretics (thiazides, loop
diuretics and aldosterone antagonists), β-blockers, inhibitors of the
renin-angiotensin system (angiotensin-converting enzyme inhibitors
and angiotensin type-1 receptor blockers), and vasodilators (calcium-
channel blockers and α-blockers). For microalbuminuria, measured in
Flemish only, we additionally adjusted models for sex, age, and body
mass index. We expressed multivariable-adjusted association sizes
between indexes of renal function and circulating MGP for a dou-
bling of the biomarker. We determined differences in these associa-
tions between country of origin or ethnicity from the appropriate
interaction terms. We also used multivariable mixed models, in
which country, ethnicity or both were introduced as random effects
and the other covariables as ﬁxed effects.
Table 1
Characteristics of participants.
Characteristic White Flemish White South Africans Black South Africans P
Number of participants (%)
All participants in category 1166 362 352
Women 598 (51.3) 205 (56.6) 184 (52.3) 0.20
Smokers 256 (22.0) 53 (14.6)† 211 (59.9)§ b0.0001
Drinking alcohol 720 (61.8) 238 (65.8) 240 (68.2) 0.060
Hypertension 337 (28.9) 48 (13.3)§ 120 (34.1)§ b0.0001
Antihypertensive treatment 168 (14.4) 71 (19.6)* 0 (0)§ b0.0001
Diabetes mellitus 53 (4.6) 27 (7.5)* 10 (2.8)† 0.013
Previous cardiovascular disease 35 (3.0) 3 (0.8)§ 2 (0.6) b0.0001
Mean (SD) of characteristic
Age (years) 38.2 (15.8) 40.3 (12.9)* 40.9 (11.5) 0.0018
Body mass index (kg/m2) 25.4 (4.3) 27.7 (5.8)§ 24.0 (6.9)§ b0.0001
Systolic pressure (mm Hg) 125.9 (14.8) 119.1 (15.9)§ 125.4 (20.7)§ b0.0001
Diastolic pressure (mm Hg) 78.5 (10.2) 78.1 (9.8) 84.6 (13.3)§ b0.0001
Heart rate (beats per minute) 66.2 (9.3) 67.5 (9.2)* 71.2 (13.4)§ b0.0001
Serum total cholesterol (mmol/L) 5.14 (1.05) 5.86 (1.42)§ 4.36 (1.08)§ b0.0001
Serum HDL cholesterol (mmol/L) 1.43 (0.40) 1.38 (0.41) 1.49 (0.63)† 0.0073
HDL-to-total cholesterol ratio 0.29 (0.09) 0.24 (0.08)§ 0.35 (0.12)§ b0.0001
Plasma glucose (mmol/L) 5.02 (1.22) 5.54 (1.19)§ 5.13 (1.03)§ b0.0001
Serum creatinine (μmol/L) 85.6 (14.8) 72.8 (12.7)§ 67.4 (12.7)§ b0.0001
eGFR (mL/min/1.73 m2) 89.5 (19.8) 100.3 (20.3)§ 121.8 (21.7)§ b0.0001
Geometric mean (IQR) of characteristic
γ-glutamyltransferase (units/L) 17.8 (12.0–24.0) 30.5 (19.0–41.7)§ 66.1 (30.5–125.9)§ b0.0001
dp-ucMGP (μg/L) 3.68 (2.60–5.31) 6.54 (5.31–8.82)§ 3.20 (2.07–6.54)§ b0.0001
Abbreviations: dp-ucMGP, desphospho-uncarboxylatedmatrix Gla protein; IQR, interquartile range; HDL, high-density lipoprotein. To convert dp-ucMGP from μg/L into pmol/L, multiply
by 94.299. Hypertensionwas a blood pressure of ≥140mmHg systolic or ≥90mmHg diastolic, or use of antihypertensive drugs. Diabetesmellitus was a fasting blood glucose ≥7.0mmol/L
(126mg/dL) or use of antidiabetic agents. P values denote the signiﬁcance of the overall difference in prevalence or mean between groups. Signiﬁcance of the difference with the left ad-
jacent group: * P ≤ 0.05; † P ≤ 0.01; ‡ P ≤ 0.001; § P ≤ 0.0001.
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3.1. Characteristics of Participants
Table 1 provides the characteristics of participants by ethnic
group. eGFR was signiﬁcantly lower in white Flemish than in white
South Africans and in white compared with black South Africans
(P b 0.0001; Table 1). Indeed, eGFR averaged (SD) 89.5 (19.8) mL/min/
1.73 m2 (range, 31.6–148.9) in Flemish, 100.3 (20.3) mL/min/1.73 m2
(range, 39.0–156.5) in white South Africans, and 121.8 (21.7) mL/min/
1.73m2 (range, 58.4–184.7) in black South Africans (Table 1). Circulating
dp-ucMGP was lower in black South Africans than in white Flemish
(P = 0.002), who in turn had lower dp-ucMGP levels than white
South Africans (P b 0.0001). The geometric mean concentrations were
3.20 μg/L (range, 0.22–15.0) in black South Africans, 3.68 μg/L
(0.23–27.8) in white Flemish, and 6.54 μg/L (0.56–25.6) in black South
Africans. In Flemish, the geometric mean of t-ucMGP was 45.2 (range,
3.35–168.1) mg/L.
In Flemish, in whom blood samples were collected from 29 April
1996 until 29 November 2011 (5th to 95th percentile interval, 14 Octo-
ber 1996 until 18 July 2005), the MGP distributions did not materially
differ according to the date of blood sampling (Fig. S2). Compared
with Africans (P ≤ 0.0004), Flemish were younger (38.2 vs. 40.6 years)
and had lower plasma glucose (5.02 vs. 5.34 mmol/L) and serum
γ-glutamyltransferase (17.8 vs. 44.7 units/L). Compared with blacks
(P ≤ 0.0007), whites had lower diastolic pressure (78.4 vs.
84.6 mmHg), lower heart rate (66.5 vs. 71.2 beats per minute) and
a lower prevalence of hypertension (385 [25.2%] vs. 120 [34.1%]),
whereas the opposite was true for treatment rates of hypertension
(239 [62.3%] vs. 0 [0%]). Men compared with women were more
likely to be smokers among Flemish (139 [24.5%] vs. 117 [19.6%]) and
Africans (156 [48.0%] vs. 108 [27.8%]) or to report alcohol intake (433
[76.2%] vs. 287 [48.0%] and 257 [79.1%] vs. 221 [56.8%], respectively).
The prevalence of HIV carrier state was 1 (0.3%) and 104 (29.6%)
among white and black Africans.
In Flemish (Fig. S3), dp-ucMGP increased whereas eGFR decreased
with age. Furthermore, in Flemish (Table S1), age, body mass index,systolic and diastolic blood pressure, prevalence of hypertension,
blood glucose and serum total cholesterol and γ-glutamyltransferase
increased (P ≤ 0.029) across thirds of the dp-ucMGP distributions,
whereas HDL cholesterol and the HDL-to-total cholesterol ratio showed
opposite trends (P ≤ 0.022). These observations were consistent among
white and black Africans (Table S2). Measurements of t-ucMGP were
available in Flemish only (Table S3). Body mass index, total cholesterol
and γ-glutamyltransferase increasedwith higher t-ucMGP (P ≤ 0.0006),
whereas the opposite was the case for HDL cholesterol and the HDL-to-
total cholesterol ratio (P ≤ 0.0033).
3.2. Unadjusted Analyses of Renal Function
Among 1166 Flemish, 543 (46.6%) were in stage 1 of chronic kidney
disease, 563 (48.3%) in stage 2, and 60 (5.2%) in stage 3; among 714
South Africans, these numbers were 573 (80.2%), 129 (18.1%), and 12
(1.7%), respectively (Table 2). Only 7 Flemish and 2 white Africans had
an eGFR less than 45 mL/min/1.73 m2. No participant of either country
had an eGFR below 30 mL/min/1.73 m2. Across increasing categories
of dp-ucMGP (Table 2 and Fig. S4), eGFR decreased (P b 0.0001) and
the prevalence of chronic kidney disease increased (P ≤ 0.0093).
Among Flemish participants, microalbuminuria was present in 53
(4.6%), but was not associated with dp-ucMGP (Table 2; P ≥ 0.59). Nei-
ther eGFR nor microalbuminuria was associated with t-ucMGP
(P ≥ 0.32; Table S4 and Fig. S4).
Unadjusted analyses of dp-ucMGP as continuous variable appear in
Table S5. eGFR decreased (P b 0.0001) and the risk of renal dysfunction
increased (P ≤ 0.024) with higher dp-ucMGP in white Flemish (n =
1166), black South Africans (n = 352), all South Africans (n = 714),
and in all participants combined (n= 1880), whereas none of these as-
sociations was signiﬁcant in white South Africans (n = 362; P ≥ 0.25).
3.3. Multivariable-Adjusted Analyses
In multivariable-adjusted analyses with effect sizes expressed for a
doubling of dp-ucMGP (Table 3), eGFR decreased by 1.46 mL/min/
1.73 m2 (P = 0.023) in Flemish and by 2.78 mL/min/1.73 m2 (P =
Table 2
Renal function by cohort and thirds of the dp-ucMGP distribution.
Characteristic Category of dp-ucMGP P
FLEMENGHO
Limits, (μg/L) b3.02 3.02–4.75 ≥4.75
Number of participants (%)
All participants in category 388 389 389
Microalbuminuria 19 (4.9) 13 (3.3) 21 (5.4) 0.36
Stage of chronic kidney disease
1 200 (51.6) 196 (50.4) 147 (37.8)†
9=
;
b0.0001
2 184 (47.4) 176 (45.2) 203 (52.2)
3 4 (1.0) 17 (4.4)† 39 (10.0)†
Mean (SD) of characteristic
Serum creatinine (μmol/L) 84.8 (12.6) 85.2 (14.7) 86.7 (16.8) 0.19
eGFR (mL/min/1.73 m2) 92.7 (17.6) 90.9 (19.8) 85.0 (21.1)§ b0.0001
Geometric mean (IQR) of characteristic
Urinary ACR (mg/mmol) 0.79 (0.45–1.35) 0.78 (0.41–1.44) 0.81 (0.45–1.38) 0.73
24-h microalbuminuria (mg) 8.5 (5.0–15.1) 8.1 (4.5–15.1) 8.5 (4.9–15.1) 0.59
SAfrEIC
Limits, (μg/L) b4.39 4.39–7.20 ≥7.20
Number of participants (%)
All participants in category 237 238 239
Stage of chronic kidney disease
1 207 (87.3) 187 (78.6) 179 (74.9)
9=
;
0.0093
2 28 (11.8) 45 (18.9) 56 (23.4)
3 2 (0.8) 6 (2.5) 4 (1.7)
Mean (SD) of characteristic
Serum creatinine (μmol/L) 68.1 (12.4) 71.3 (13.2)† 71.0 (13.0) 0.014
eGFR (mL/min/1.73 m2) 121.2 (23.3) 108.1 (23.2)§ 103.5 (20.6)* b0.0001
Abbreviations: dp-ucMGP, desphospho-uncarboxylated matrix GLA protein; eGFR, estimated glomerular ﬁltration rate according to the Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation; IQR, interquartile range; ACR, urinary albumin-to-creatinine ratio. Microalbuminuriawas an albumin-to-creatinine ratio ≥ 3.5mg/mmol inwomen and ≥2.5mg/
mmol in men. Chronic kidney disease was staged according to the National Kidney Foundation (KDOQI) guideline as eGFR ≥90, 60–89, 30–59 mL/min/1.73 m2. P values denote the sig-
niﬁcance of the difference in prevalence ormean across thirds of the distribution of dp-ucMGP. Signiﬁcance of the differencewith the adjacent lower third: * P ≤ 0.05; † P ≤ 0.01; ‡ P ≤ 0.001;
and § P ≤ 0.0001.
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weaker association in white Africans (−1.00 mL/min/1.73 m2; P =
0.56). These ﬁndings remained consistent if models for Flemish were
adjusted for individual antihypertensive drug classes instead of all
classes combined in a summary variable or if in blacks HIV carrier status
was introduced as an additional covariable (Table 3). In Flemish, for a
doubling of t-ucMGP, eGFR increased by 1.91 mL/min/1.73 m2 (95%
conﬁdence interval [CI], 0.08 to 3.73; P = 0.038). In models including
both MGP conformations, the effect sizes were −1.42 mL/min/Table 3
Adjusted associations of renal function with desphospho-uncarboxylated matrix Gla
protein.
Participants
model
eGFR (mL/min/1.73 m2) Chronic kidney disease
Association size (95% CI) P Odds ratio (95% CI) P
White Flemish
Standard −1.46 (−2.71 to−0.20) 0.0230 1.17 (1.01 to 1.36) 0.033
Alternative −1.57 (−2.83 to−0.31) 0.0146 1.19 (1.02 to 1.38) 0.022
White South
Africans
−1.00 (−4.42 to 2.42) 0.56 1.03 (0.70 to 1.53) 0.87
Black South
Africans
Standard −2.78 (−4.45 to−1.11) 0.0012 1.29 (0.94 to 1.79) 0.12
Alternative −2.80 (−4.47 to−1.13) 0.0011 1.30 (0.94 to 1.80) 0.12
All Whites −1.33 (−2.52 to−0.12) 0.0314 1.15 (1.00 to 1.31) 0.049
All South
Africans
−2.55 (−4.02 to 1.08) 0.0007 1.19 (0.94 to 1.52) 0.16
All participants −2.07 (−3.02 to−1.12) b0.0001 1.17 (1.04 to 1.33) 0.011
Association sizes and odds ratios express the change in the dependent variable associated
with a doubling of desphospho-uncarboxylatedmatrix Gla protein (dp-ucMGP). Standard
models accounted formean arterial pressure, heart rate, plasmaglucose, HDL-to-total cho-
lesterol ratio, γ-glutamyltransferase, smoking, and antihypertensive drug treatment. The
alternative model in FLEMENGHO participants was adjusted for treatment with diuretics,
β- blockers, inhibitors of the renin-angiotensin system, and vasodilators instead of all an-
tihypertensive drug classes combined in a single variable. The alternative model in blacks
was additionally adjusted for HIV carrier state. Covariables coding for the strata were
entered into models including participants from two countries or two ethnicities. Interac-
tions of dp-ucMGP with country of origin or ethnicity were not signiﬁcant (P ≥ 0.075).1.73 m2 (CI,−2.66 to−0.19; P = 0.026) for dp-ucMGP and 1.86 (CI,
0.03 to 3.68; P=0.044) for t-ucMGP (Fig. 1). In models additionally ad-
justed for country of origin, ethnicity or both, the association sizes of
eGFR with dp-ucMGP were −1.33 (P = 0.031) in all whites (n =Fig. 1. Multivariable-adjusted associations of estimated glomerular ﬁltration rate
with circulating matrix Gla proteins in Flemish participants. The plane shows the
independent associations of eGFR (glomerular ﬁltration rate derived from the serum
creatinine concentration by Chronic Kidney Disease Epidemiology Collaboration
equation) with dp-ucMGP (desphospho-uncarboxylated matrix Gla protein) and
t-ucMGP (total uncarboxylated matrix Gla protein). The plotted plane was standardized
to the mean distribution in the whole study population of mean arterial pressure, heart
rate, HDL-to-total cholesterol ratio, plasma glucose, smoking, γ-glutamyltransferase,
and treatment with diuretics, β- blockers, inhibitors of the renin-angiotensin system
and vasodilators. dp-ucMGP increases with vitamin K deﬁciency, whereas t-ucMGP
decreases with prevalent calciﬁcations.
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(P b 0.0001) in all participants (n = 1880). Interactions of dp-ucMGP
with country (P ≥ 0.39) or ethnicity (P ≥ 0.075) were not signiﬁcant.
Table 3 lists the multivariable-adjusted odds ratios describing the
risk of moving up one stage in the classiﬁcation of chronic kidney dis-
ease associated with a doubling of dp-ucMGP. The odds ratios
amounted to 1.17 (P = 0.033) in Flemish, and 1.29 (P = 0.12) and
1.03 (P=0.87) in black and white South Africans. Alternatively adjust-
ed models (Table 3) in Flemish and black Africans were conﬁrmatory.
The odds ratios in multivariable-adjusted logistic models that addition-
ally include stratiﬁcation variableswere 1.15 (P=0.049) inwhites, 1.19
(P=0.16) in Africans, and 1.17 (P=0.011) in all participants (interac-
tion P-values, ≥0.16). Mixed models with eGFR or stage of chronic kid-
ney disease as dependent variable and including country of origin and
ethnicity modeled as random effects and the other covariables as ﬁxed
effects also produced consistent results.
4. Discussion
We assessed the association of renal microvascular function as
exempliﬁed by eGFR with both circulating dp-ucMGP and t-ucMGP in
a multi-ethnic population study. High dp-ucMGP is a marker of vitamin
K deﬁciency (Dalmeijer et al., 2012), whereas t-ucMGP decreases with
prevalent vascular calciﬁcation (Cranenburg et al., 2009; Schurgers
et al., 2005). In Flemish, with adjustments applied for covariables,
eGFR measured on a continuous scale was inversely associated with
dp-ucMGP and positively with t-ucMGP. Furthermore, in categorical
analyses, the risk of moving up one stage in the classiﬁcation of chronic
kidney disease increased with higher dp-ucMGP. We conﬁrmed the in-
verse association of eGFRwith dp-ucMGP in black South Africans and all
South Africans combined. The potential relevance of these observations
relates to the global epidemic of chronic kidney disease (Wang et al.,
2012; Vos et al., 2012). The Global Burden of Disease Study 2010 collab-
oration estimated that worldwide 0.403 million of nearly 50 million
deaths occurring annually, were attributable to renal failure in 1990
and 0.736 in 2010, representing an increase by 82.3% (Wang et al.,
2012). Across all ages, over the same time span, the years lived with
chronic kidney disease increased by 57.1% from 2.56 to 4.02 million,
while the disability-adjusted life years, a metric that captures both
premature mortality and the prevalence of ill-health caused by renal
disease increased by 51.7% from 13.9 to 21.2 million (Vos et al., 2012).
Circulating levels of vitamin K are rarely measured in clinical prac-
tice, because of the complexity of the assay and the lack of a high-
throughput method (Riphagen et al., 2015), and because plasma levels
only reﬂect dietary intake (vitamin K1; phylloquinone) and production
by the gutmicroﬂora (vitamin K2;menaquinones) over fewhourswith-
out any indication of functionality (Dalmeijer et al., 2012; Westenfeld
et al., 2012), whereas what really counts is the tissue level of active car-
boxylated MGP. We convincingly showed that high levels of dp-ucMGP
indicate poor vitamin K status (Dalmeijer et al., 2012; Westenfeld et al.,
2012). For instance, among60middle-aged healthy volunteers random-
ized in a placebo-controlled double-blind trial, circulating dp-ucMGP
dropped dose-dependently by 31% and 46% in response to supplemen-
tation with 180 μg and 360 μg of menaquinone-7 (vitamin K2) daily
for 12 weeks, whereas no changes occurred in t-ucMGP (P = 0.23)
(Dalmeijer et al., 2012). Along similar lines, among 174 patients with
chronic kidney disease, stages 3 to 5, the criteria for vitaminK deﬁciency
were met in 6%, 60% and 97% based on plasma levels of phylloquinone,
percent uncarboxylated osteocalcin, or proteins induced by vitamin K
absence (PIVKA; des-γ-carboxy-prothrombin) (Holden et al., 2010).
Poor vitamin K status in patients with chronic kidney disease or on he-
modialysis not only results from higher needs of activation of MGP in
the presence of the increased risk of arterial calciﬁcation, but also from
lower dietary intake compared with healthy controls (Cranenburg
et al., 2012). By far, the most extensive vascular calciﬁcations occur in
patients with chronic kidney disease (Lanzer et al., 2014; Moe andChen, 2004). In keeping with our current ﬁndings, impaired inhibition
of calciﬁcation might be a major player underlying the high risk of arte-
rial calciﬁcation, macrovascular complications, and ultimately death in
patients with chronic kidney disease (Moe and Chen, 2004). However,
studies in selected patients with renal dysfunction cannot be general-
ized. In our Flemish population study, circulating dp-ucMGP measured
at baseline, over 14.1 years of follow-up, predicted cardiovascular mor-
tality and fatal combined with nonfatal cardiovascular events (Liu et al.,
2015). Such events are caused by macrovascular disease. Our current
cross-sectional studies in Flemish and South Africans, extend these ob-
servations to renal function, as exempliﬁed by eGFR, a microcirculatory
trait (Chade, 2013; Navar et al., 2008). In Flemish, in whom we
measured the urinary excretion of microalbumin, the association with
dp-ucMGP was not signiﬁcant. However, in this Flemish population
sample, the amount of microalbumin excreted and the prevalence of
microalbuminuria (4.6%) were too low to reach statistical signiﬁcance.
Both fetuin-A and MGP are inhibitors of calciﬁcation, but have com-
plementary, albeit distinct, biological roles. Fetuin-A is a liver-secreted
protein that is not vitamin K dependent and complexes with calcium
and phosphate in the circulation to prevent precipitation of these min-
erals in tissues (Heiss et al., 2003; Schafer et al., 2003). In genetically
engineered mice, knocking out MGP or fetuin-A results in arterial or
soft tissue calciﬁcation or both (Schafer et al., 2003; Luo et al., 1997). Se-
lectively reintroducingMGP expression in the liver of theMGP deﬁcient
mice, produced circulating MGP levels 6- to 10-fold higher than in wild
type animals (Murshed et al., 2004). The MGP originating from the
transgene conserved its biological activity in vitro, but did not inhibit ar-
terial calciﬁcation (Murshed et al., 2004). Thus, fetuin-A is a systemically
active protein, whereas MGP is locally synthesized and activated in
vascular smooth muscle cells and prevents arterial calciﬁcation
through local effects in the arterial wall. The recently introduced cal-
cium propensity test (Pasch et al., 2012) measures a patient's sys-
temic predisposition to extracellular matrix mineralization, which
is controlled by fetuin-A, but probably not by locally synthesized MGP,
as no correlation exits between circulating levels of fetuin-A and MGP
(Javadzadeh et al., 2015).
In keeping with a previous report in 842 out-patients with stable
cardiovascular disease (Parker et al., 2009), t-ucMGP correlated pos-
itively with eGFR. t-ucMGP, in the literature often referred to as
ucMGP, predominantly consists of phosphorylated MGP and at vari-
ance with dp-ucMGP is not a biomarker of vitamin K status, but
lower levels reﬂect more extensive cardiovascular calciﬁcations
(Cranenburg et al., 2009; Schurgers et al., 2005). t-ucMGP accumulates
at arterial calciﬁcation sites, possibly by binding through its negatively
charged phosphoserine residues (Cranenburg et al., 2009; Schurgers
et al., 2005). Upregulation of MGP transcription in response to vascular
stress inﬂuences circulating t-ucMGP levels (Cranenburg et al., 2009). In
40 patients on hemodialysis, the mean t-ucMGP level was signiﬁcantly
lower than in healthy age-matched controls. Additionally, higher
coronary calciﬁcation scores determined by multi-slice computed to-
mography were associated with lower t-ucMGP levels (r = −0.41;
P= 0.009). This correlation persisted after adjustment for age, dialysis
vintage, and high-sensitivity C-reactive protein as marker of inﬂamma-
tion (Cranenburg et al., 2009).
Several points related to the ethnic and lifestyle differences in our
study deserve to be speciﬁcally highlighted. First, Flemish were ran-
domly recruited from the general population. South Africans were also
enrolled from the local community via advertisements and by invitation
by health workers, but only qualiﬁed for participation if they were
healthy. This difference in recruitment strategy explains the lower prev-
alence of hypertension and higher eGFR among SouthAfrican compared
with Flemish whites. Second, compared with whites, blacks have a
higher glomerular ﬁltration rate indicative of glomerular hyperﬁltration
(Kotchen et al., 2000). eGFR as estimated from serum creatinine by the
CKD-EPI equation (Levey et al., 2009) accounts for this well established
ethnic difference. In addition, blacks compared with whites are more
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Hara et al., 2015). The observation of a higher eGFR (Kotchen et al.,
2000) and higher prevalence of hypertension among blacks (Burt
et al., 1995; Hara et al., 2015) compared with whites is therefore in
keeping with the literature and constitutes an external validation of
our study. Finally, the association between eGFR and dp-ucMGP in
white South Africans, although directionally consistent with the associ-
ation in white Flemish and in black South Africans, did not reach signif-
icance. However, dp-ucMGP levels in white South Africans were
approximately twice as high compared with white Flemish and their
black counterparts. Elevated dp-ucMGP levels with little interindividual
variation in white South Africans in the presence of normal variation in
eGFR may have weakened the association (Fig. S5). Low dp-ucMGP re-
ﬂects high intake of vitamin K, mostly vitamin K2. Fermented products
are the main dietary source of menaquinones. Europeans get most of
their intake from cheese. In South Africa, cheese consumption is much
lower than in Europe. The per capita consumption is approximately
0.9 kg per year compared to 19.2 kg per year in Belgium (data for
2011 available at http://www.helgilibrary.com/indicators/index/
cheese-consumption-per-capita). Traditionally, consumption of
fermented foods is high in black populations of sub-Saharan Africa, par-
ticularly in rural areas, andmakes up for the cheese as source of vitamin
K in Flemish. Moreover, abuse of antibiotics is very common in South
Africa (Gelband and Duse, 2011), in particular among afﬂuent whites,
whichmight adversely affect production of vitamin K2 by the gutmicro-
ﬂora. In 2000, the per capita use of antibiotics was approximately 20
standard units in Belgium and 15 standard units in South Africa, all eth-
nicities combined (Gelband et al., 2015). From 2000 to 2010, the per
capita use decreased by 18% in Belgium (Gelband et al., 2015) as a con-
sequence of policies instituted by the Federal Government (Goossens,
2000), but over the same time span rose by 280% in South Africa
(Gelband et al., 2015).
The current study must be interpreted within the context of its
strengths and potential limitations. A strong point is that we measured
both dp-ucMGP and t-ucMGP in a relatively large sample representative
of the Flemish population and that we replicated the inverse association
of eGFR or chronic kidney disease with dp-ucMGP in a multi-ethnic
South African cohort. We demonstrated that our MGP assay was not
sensitive to long-term storage of blood samples (Fig. S2). Generation
of creatinine differs among ethnic groups (Stevens et al., 2011; Udler
et al., 2015) and HIV carrier state affects estimates of eGFR and chronic
kidney disease (Seape et al., 2016). However, among the creatinine-
based equations, the CKD-EPI approach (Levey et al., 2009) performed
best in estimating renal function in treatment-naïve HIV patients
(Seape et al., 2016) and South African blacks (Matsha et al., 2013), and
in predicting risk in over one million people recruited from 40 multi-
ethnic cohort studies (Matsushita et al., 2012).
Among the potential limitations of our current study is its cross-
sectional design, which precludes direct causal inference. Second, the
historical record of migration into South Africa implies that genetic ad-
mixture is common place (Stull et al., 2014). Ethnicity among our South
African participants was self-reported. However, for research purposes,
experts still assign great value to racial self-categorization (Risch et al.,
2002) and South African studies demonstrated good agreement
between racial self-categorization and forensic (Stull et al., 2014) and
genetic (Patterson et al., 2010)markers of race. Third, because of admix-
ture and diversity in lifestyle and living environment, whites of Flemish
and South African originmust bemore dissimilar than just suggested by
ethnicity. Finally, we could not reliably assess the dietary intake of
vitamin K, because validated food frequency questionnaires and food
composition tables are unavailable for use in Flemish or South African
populations.
Notwithstanding potential limitations, our ﬁndings may have
important clinical implications. High levels of plasma dp-ucMGP are a
proxy for vitamin K deﬁciency (Dalmeijer et al., 2012; Westenfeld
et al., 2012). Levels ranging from ~1.4 to ~4.6 μg/L are probably optimalin terms of the risk of mortality andmacrovascular cardiovascular com-
plications (Liu et al., 2015). In Flemish, the 4.6 μg/L threshold
corresponded with the 65th percentile of the dp-ucMGP distribution,
indicating that 35% of Flemish might be vitamin K deﬁcient. In South
Africa, lactic acid bacteria dominate the microﬂora of fermented milk
products (Beukes et al., 2001), but with urbanization and the associated
socioeconomic and lifestyle changes, traditional technologies for the
production of fermented foods will eventually be lost together with
the associated micro-organisms, thereby increasing the risk of vitamin
K deﬁciency (Anukam and Reid, 2009). The recommended dietary al-
lowance for vitamin K is 1 μg per kilogram of body weight per day,
which is sufﬁcient to ensure normal hemostasis (Weber, 2001). However,
in apparently healthy individuals, a substantial fraction of MGP remains
in the uncarboxylated forms (Schurgers et al., 2005). This raises the ques-
tion as to whether the present recommended dietary allowance for vita-
min K intake is sufﬁcient to prevent macrovascular disease. In Swiss
randomly recruited from the general population, aortic pulsewave veloc-
ity was positively associated with plasma dp-ucMGP, even after adjust-
ment for cardiovascular risk factors and renal dysfunction (Pivin et al.,
2015). Vitamin K supplementation reduced aortic pulse wave velocity
in healthy postmenopausal women (Knapen et al., 2015). Assuming re-
versibility, our current ﬁndings extend the protective role of vitamin K
from the macrocirculation to renal function and possibly reveal a poten-
tial for prevention by supplementation, for instance by biologically
enriched fermented vegetable or dairy products. Moreover, vitamin K
has a very wide safety range, irrespective whether the sources are
leafy vegetables (phylloquinone; vitamin K1) or fermented foods
(menaquinones; vitamin K2) (Weber, 2001). While dp-ucMGP might be
a biomarker relevant to prevent disease, circulating t-ucMGP might ﬁnd
its way to clinical application as a marker of arterial calciﬁcation at a
stage when macrovascular disease is still asymptomatic.
5. Conclusion
Inwhite Flemish and black SouthAfricans recruited from the general
population, eGFR decreased and the risk of renal impairment increased
with higher dp-ucMGP, a marker of vitamin K deﬁciency. These epide-
miological ﬁndings support the concept that active MGP might not
only inhibit calciﬁcation in large arteries, as was well known before
(Knapen et al., 2015), but might also protect renal function. Our obser-
vations potentially highlight new avenues for promoting renal health,
for instance by increasing the dietary intake of vitamin K either by sup-
plementation or by increasing the intake of nutrients rich in vitamin K.
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